8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
US health technology assessor the Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of three new treatments targeting the B-cell maturation antigen (BCMA) for heavily pre-treated patients with triple class refractory multiple myeloma (TCRMM) who have cycled through numerous previous lines of therapy: 12 May 2021
MiNA Therapeutics has today announced a global research collaboration with US pharma major Eli Lilly to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform. 11 May 2021
Shares US drug developer Organicell Regenerative Medicine were up a massive 29% at $0.36 by mid-morning, after it announced that its Zofin therapy has been approved by Pakistani regulators to be used for a COVID-19 patient on compassionate grounds. 11 May 2021
US biotech Inovio might be behind competitors in the development of a COVID-19 vaccine, but the company has provided a reminder that it is still in the game. 11 May 2021
The US Food and Drug Administration has expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents through 15 years of age. 11 May 2021
Slow progress in preparing regulatory submissions will see US vaccines developer Novavax send its COVID-19 vaccine, NVX-CoV2373, for approval in the third quarter at the earliest. 11 May 2021
Eli Lilly has inked royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of generic medicines, Cipla, Lupin and Sun Pharmaceutical Industries, to expedite availability of its arthritis drug baricitinib for the treatment of COVID-19 patients in India. 10 May 2021
Mainz, Germany-based BioNTech has announced plans to expand its global footprint to Asia with the establishment of a new regional headquarters in Singapore. 10 May 2021
Chugai Pharmaceutical has reached agreement with the Japanese government regarding the antibody cocktail casirivimab and imdevimab (formerly known as REGN-COV2), which is being investigated as a potential treatment for COVID-19. 10 May 2021
Belgium-based biotech Galapagos has announced operational highlights and plans for refocussing of its clinical pipeline, along with its first-quarter 2021 financial results. 10 May 2021
The PARP inhibitor pamiparib has received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of patients with germline BRC (gBRCA) mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy. 8 May 2021
AstraZeneca’s Tagrisso (osimertinib) is the beneficiary of the UK’s Medicines and Healthcare products Regulatory Agency’s (MHRA) first authorization under Project Orbis, a global program designed to deliver faster patient access to innovative cancer drugs. 7 May 2021
US pharma giant Pfizer and German partner BioNTech have announced the initiation of a Biologics License Application (BLA) with the US Food and Drug Administration for approval of their mRNA vaccine to prevent COVID-19 – called Comirnaty or BNT162b2 - in individuals 16 years of age and older. 7 May 2021
Minutes from the May meeting of the European Medicines Agency’s safety committee show the panel has reaffirmed the positive benefit-risk ratio of approved coronavirus vaccines. 7 May 2021
The European Medicines Agency (EMA) has started a rolling review of data on sotrovimab (previously VIR-7831), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. 7 May 2021
An estimate-beating first quarter performance lifted shares in New York’s Regeneron Pharmaceuticals over 3% on Thursday, with revenues up 38% at $2.5 billion. 7 May 2021
Swiss–American biotechnology CRISPR Therapeutics and Nkarta, a biopharmaceutical company developing engineered NK cell therapies to treat cancer, have entered a strategic partnership to research, develop, and commercialize CRISPR/Cas9 gene-edited cell therapies for cancer. 7 May 2021
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.